SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-110537
Filing Date
2023-10-20
Accepted
2023-10-20 17:00:27
Documents
12
Period of Report
2023-10-16
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2328605d1_8k.htm   iXBRL 8-K 26059
  Complete submission text file 0001104659-23-110537.txt   202533

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA otlk-20231016.xsd EX-101.SCH 3304
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE otlk-20231016_lab.xml EX-101.LAB 34750
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE otlk-20231016_pre.xml EX-101.PRE 22381
6 EXTRACTED XBRL INSTANCE DOCUMENT tm2328605d1_8k_htm.xml XML 3393
Mailing Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830
Business Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

IRS No.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37759 | Film No.: 231337647
SIC: 2836 Biological Products, (No Diagnostic Substances)